The MLP Ventures-funded Discovery Labs says it is “bending the rules” in its efforts to stimulate R&D at the former GlaxoSmithKline site through a limited governance financial model. In April 2018, GlaxoSmithKline (NYSE: GSK) sold its R&D campus in King of P...
Amicus Therapeutics bought a spinout of Nationwide Children’s Hospital last year as part of a plan to become a player in the emerging field of gene therapy. Today it is providing the first evidence, in humans, that the investment could pay dividends. The results Amicu...
Roche has agreed to buy Spark Therapeutics for $4.8 billion, the latest strong signal that major pharmaceutical companies are ready to gamble on the promise of gene therapy despite its uncertain commercial prospects. The Swiss pharma giant will pay $114.50 per share, in...
Fresh off finally winning an FDA nod for its first product, Amicus Therapeutics is getting in on the gene therapy renaissance. This morning, Cranbury, NJ-based Amicus (NASDAQ: FOLD) agreed to pay $100 million up front to buy a privately held company, Celenex, spun out o...
[Updated 1/23/18, 11:21 a.m. See below.] Two therapies from the emerging field of engineered T cells won FDA approval to treat blood cancers last year, and the scramble is on to treat more types of cancer. Led by Usman “Oz” Azam (pictured above), the executi...